3D Engineered Model of Microscopic Colorectal Cancer Liver Metastasis for Adjuvant Chemotherapy Screens
用于辅助化疗筛选的显微结直肠癌肝转移 3D 工程模型
基本信息
- 批准号:10556192
- 负责人:
- 金额:$ 31.67万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-01-01 至 2028-12-31
- 项目状态:未结题
- 来源:
- 关键词:3-DimensionalAccountingAdjuvant ChemotherapyAdjuvant TherapyArchitectureBenchmarkingBiocompatible MaterialsBiological MarkersBiomedical EngineeringCancer PatientCause of DeathCellsCessation of lifeChemoresistanceClinicClinicalClinical ManagementClinical TreatmentColorectal CancerCurative SurgeryDetectionDiseaseDisease-Free SurvivalDisseminated Malignant NeoplasmDropsElementsEngineeringEnsureExcisionExtracellular MatrixFDA approvedFamily suidaeFutureGoalsHumanImageIn VitroInfiltrative GrowthInjectionsIntestinesLibrariesLiverMalignant NeoplasmsMalignant neoplasm of ovaryMetastatic Neoplasm to the LiverMethodsMicrometastasisMicroscopicMicroscopyModelingNatureNeoplasm MetastasisOncologyOperative Surgical ProceduresOutcomePatientsPharmaceutical PreparationsPhase I Clinical TrialsPositioning AttributePre-Clinical ModelRecurrenceRegenerative MedicineReproducibilityResearchResearch SupportResidual CancersResidual NeoplasmRodentSamplingTechnologyTestingTherapeuticTherapeutic UsesTissue EngineeringTranslatingValidationWorkcancer initiationcancer therapycolon cancer patientscolorectal cancer metastasishigh riskhigh-throughput drug screeningin vitro Modelin vivo Modelinnovationnoveloptical imagingpatient derived xenograft modelpatient responsepatient stratificationpre-clinicalpreventradiological imagingscaffoldscreeningtherapeutic targettumor DNAtumor microenvironment
项目摘要
PROJECT SUMMARY
50% of colorectal cancer (CRC) patients develop liver metastasis (CRLM). Despite adjuvant
chemotherapy and surgery, 75% of CRLM recurs due to microscopic residual disease (~1-3mm) that
escapes radiographic detection. The objective of this proposal is to engineer and utilize an adjuvant
chemotherapy screening platform specific to microscopic CRLM, to identify therapeutics that can
eradicate microscopic residual disease. Preclinical models like spheroids and patient-derived xenograft
models lack the architecture and extracellular matrix (ECM) composition of the liver metastatic
microenvironment. We hypothesize that by engineering the liver metastatic microenvironment, we
can produce reproducible instances of microscopic CRLM that can be used for therapeutic screening.
Engineered microscopic CRLM models will include: i) decellularized porcine liver biomatrix scaffolds
that contain both liver ECM composition and 3D architecture; ii) microscopic spheroids from cells
established from patient-derived xenografts of stage IV CRLM. Our methods offer advantages over
other decellularized models by: i) using patient-derived cells; and ii) using optical imaging to
quantitatively benchmark the establishment of microscopic CRLM; iii) using orthogonal validation
including clinical patient-response benchmarking of engineered models to therapeutics; iv) being
medium- and high-throughput amenable. The project will build on the PI's (Raghavan) expertise in
cancer tissue engineering, but represent significant changes in research directions: The PI's expertise
is in studying ovarian cancer initiation and chemoresistance, and this proposal focuses on CRC
metastasis and CRLM. To support these research pivots, the PI has assembled an investigative team
with expertise in clinical treatment and management of CRC (Kopetz), high-throughput drug
screening (Stephan) and microscopy (Walsh). Specific Aims proposed include: (1) : Establish and
characterize a bioengineered model of microscopic CRLM from human stage IV CRC; (2) Therapeutic
screening of microscopic CRLM using an NCI-approved library; (3) Validation of therapeutic targeting
of microscopic CRLM in orthotopic metastasis models. This will be the first instance of a
bioengineered in vitro model of microscopic CRLM. Immediate outcomes using the engineered
microscopic CRLM model include: i) screening a library of NCI-approved compounds; ii) identifying
efficacious strategies to treat microscopic CRLM. Long-term outcomes envisioned include: i) predict
the aggressiveness of microscopic residual disease, stratifying patients who are at high-risk of
recurrence; ii) testing compounds that can translate into phase I clinical trials in patients with
microscopic CRLM identified with circulating tumor DNA biomarkers.
项目摘要
50%的结直肠癌(CRC)患者发生肝转移(CRLM)。尽管有佐剂
化疗和手术后,75%的CRLM由于显微镜下残留病变(~1- 3 mm)而复发,
逃过了射线检测。该提案的目的是设计和利用佐剂
针对显微CRLM的化疗筛选平台,以确定可以
根除微观残留疾病。临床前模型,如球状体和患者源性异种移植物
模型缺乏肝转移瘤的结构和细胞外基质(ECM)组成,
微环境我们假设通过改造肝转移微环境,
可以产生可用于治疗筛选的显微CRLM的可再现实例。
工程化的微观CRLM模型将包括:i)脱细胞猪肝生物基质支架
包含肝ECM组合物和3D结构; ii)来自细胞的微观球状体
从IV期CRLM的患者来源的异种移植物建立。我们的方法提供的优势超过
其他脱细胞模型,通过:i)使用患者来源的细胞;和ii)使用光学成像,
定量基准建立微观CRLM; iii)使用正交验证
包括工程模型对治疗的临床患者反应基准; iv)
中等和高通量可接受。该项目将建立在PI(Raghavan)的专业知识基础上,
癌症组织工程,但代表了研究方向的重大变化:PI的专业知识
正在研究卵巢癌的发生和化疗耐药性,该提案侧重于CRC
转移和CRLM。为了支持这些研究重点,PI组建了一个调查小组,
具有CRC临床治疗和管理的专业知识(Kopetz),高通量药物
筛选(Stephan)和显微镜检查(沃尔什)。具体目标包括:(1):建立和
表征来自人IV期CRC的微观CRLM的生物工程模型;(2)治疗性
使用NCI-approved文库筛选显微CRLM;(3)验证治疗靶向
原位转移模型中显微镜下CRLM的变化。这将是第一个
显微CRLM的生物工程体外模型。使用设计的
微观CRLM模型包括:i)筛选NCI批准的化合物库; ii)鉴定
治疗显微镜CRLM的有效策略。预期的长期结果包括:i)预测
显微镜下残留疾病的侵袭性,对高风险患者进行分层,
ii)测试可以转化为I期临床试验的化合物,
用循环肿瘤DNA生物标志物鉴定的显微镜CRLM。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Shreya Raghavan其他文献
Shreya Raghavan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Shreya Raghavan', 18)}}的其他基金
Engineered Enteric Nervous System-Peri Neural Invasion platform to improve predictive preclinical screens in early-stage colorectal adenocarcinomas
工程肠神经系统-周围神经侵袭平台可改善早期结直肠腺癌的预测性临床前筛查
- 批准号:
10439886 - 财政年份:2021
- 资助金额:
$ 31.67万 - 项目类别:
Engineered Enteric Nervous System-Peri Neural Invasion platform to improve predictive preclinical screens in early-stage colorectal adenocarcinomas
工程肠神经系统-周围神经侵袭平台可改善早期结直肠腺癌的预测性临床前筛查
- 批准号:
10286742 - 财政年份:2021
- 资助金额:
$ 31.67万 - 项目类别:
相似海外基金
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
- 批准号:
24K16488 - 财政年份:2024
- 资助金额:
$ 31.67万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mighty Accounting - Accountancy Automation for 1-person limited companies.
Mighty Accounting - 1 人有限公司的会计自动化。
- 批准号:
10100360 - 财政年份:2024
- 资助金额:
$ 31.67万 - 项目类别:
Collaborative R&D
Accounting for the Fall of Silver? Western exchange banking practice, 1870-1910
白银下跌的原因是什么?
- 批准号:
24K04974 - 财政年份:2024
- 资助金额:
$ 31.67万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A New Direction in Accounting Education for IT Human Resources
IT人力资源会计教育的新方向
- 批准号:
23K01686 - 财政年份:2023
- 资助金额:
$ 31.67万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
An empirical and theoretical study of the double-accounting system in 19th-century American and British public utility companies
19世纪美国和英国公用事业公司双重会计制度的实证和理论研究
- 批准号:
23K01692 - 财政年份:2023
- 资助金额:
$ 31.67万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
An Empirical Analysis of the Value Effect: An Accounting Viewpoint
价值效应的实证分析:会计观点
- 批准号:
23K01695 - 财政年份:2023
- 资助金额:
$ 31.67万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Accounting model for improving performance on the health and productivity management
提高健康和生产力管理绩效的会计模型
- 批准号:
23K01713 - 财政年份:2023
- 资助金额:
$ 31.67万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
CPS: Medium: Making Every Drop Count: Accounting for Spatiotemporal Variability of Water Needs for Proactive Scheduling of Variable Rate Irrigation Systems
CPS:中:让每一滴水都发挥作用:考虑用水需求的时空变化,主动调度可变速率灌溉系统
- 批准号:
2312319 - 财政年份:2023
- 资助金额:
$ 31.67万 - 项目类别:
Standard Grant
New Role of Not-for-Profit Entities and Their Accounting Standards to Be Unified
非营利实体的新角色及其会计准则将统一
- 批准号:
23K01715 - 财政年份:2023
- 资助金额:
$ 31.67万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving Age- and Cause-Specific Under-Five Mortality Rates (ACSU5MR) by Systematically Accounting Measurement Errors to Inform Child Survival Decision Making in Low Income Countries
通过系统地核算测量误差来改善特定年龄和特定原因的五岁以下死亡率 (ACSU5MR),为低收入国家的儿童生存决策提供信息
- 批准号:
10585388 - 财政年份:2023
- 资助金额:
$ 31.67万 - 项目类别: